159 related articles for article (PubMed ID: 16925149)
1. Applying new data to manage CINV: achieving optimal outcomes through a comprehensive care model.
Padezanin S
ONS News; 2006; 21(8 Suppl):47-8. PubMed ID: 16925149
[No Abstract] [Full Text] [Related]
2. Effective interventions for CINV: NCCN Antiemesis Clinical Practice Guidelines in Oncology.
ONS News; 2004; 19(9 Suppl):17-8. PubMed ID: 15478570
[TBL] [Abstract][Full Text] [Related]
3. Survivor supportive care: can you survive the supportive care challenge?
Fonteyn ME
ONS News; 2006; 21(8 Suppl):45-6. PubMed ID: 16925148
[No Abstract] [Full Text] [Related]
4. Chemotherapy-induced nausea and vomiting (CINV): prevention, detection, and treatment--how are we doing?
ONS News; 2004; 19(9 Suppl):61-2. PubMed ID: 15478591
[TBL] [Abstract][Full Text] [Related]
5. Integrating aprepitant and palonosetron into clinical practice: a role for the new antiemetics.
Viale PH
Clin J Oncol Nurs; 2005 Feb; 9(1):77-84. PubMed ID: 15751501
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced nausea and vomiting (CINV): detection and management of postinfusion CINV--how are we doing?
Padezanin S
ONS News; 2006; 21(8 Suppl):43-4. PubMed ID: 16925147
[No Abstract] [Full Text] [Related]
7. Palonosetron (Aloxi) for prevention of nausea and vomiting due to cancer chemotherapy.
Med Lett Drugs Ther; 2004 Mar; 46(1179):27-8. PubMed ID: 15057189
[No Abstract] [Full Text] [Related]
8. New and emerging therapeutic options for the management of chemotherapy-induced nausea and vomiting.
Schwartzberg LS; Rugo HS; Aapro MS
Clin Adv Hematol Oncol; 2015 Mar; 13(3 Suppl 3):3-13, 1; quiz 2 p following 14. PubMed ID: 25856052
[TBL] [Abstract][Full Text] [Related]
9. New management strategies for CINV.
Oestreicher P
ONS Connect; 2007; 22(8 Suppl):15-6. PubMed ID: 17824546
[No Abstract] [Full Text] [Related]
10. Chemotherapy-induced nausea and vomiting: state of the art in 2006.
Schwartzberg L
J Support Oncol; 2006 Feb; 4(2 Suppl 1):3-8. PubMed ID: 16499138
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
12. Putting evidence into practice: evidence-based interventions to prevent, manage, and treat chemotherapy-induced nausea and vomiting.
Tipton JM; McDaniel RW; Barbour L; Johnston MP; Kayne M; LeRoy P; Ripple ML
Clin J Oncol Nurs; 2007 Feb; 11(1):69-78. PubMed ID: 17441398
[TBL] [Abstract][Full Text] [Related]
13. Emerging treatments in chemotherapy-induced nausea and vomiting.
Grunberg SM; Slusher B; Rugo HS
Clin Adv Hematol Oncol; 2013 Feb; 11(2 Suppl 1):1-18; quiz 2 p following 18. PubMed ID: 23598819
[TBL] [Abstract][Full Text] [Related]
14. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting.
Mori-Vogt S; Blazer M
Expert Rev Anticancer Ther; 2013 Aug; 13(8):919-36. PubMed ID: 23984894
[TBL] [Abstract][Full Text] [Related]
15. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
16. Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting.
Ruhlmann C; Herrstedt J
Expert Rev Anticancer Ther; 2010 Feb; 10(2):137-48. PubMed ID: 20131990
[TBL] [Abstract][Full Text] [Related]
17. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
Balu S; Buchner D; Craver C; Gayle J
Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
[TBL] [Abstract][Full Text] [Related]
18. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
19. Best practice management of CINV in oncology patients: II. Antiemetic guidelines and rationale for use.
Wickham R
J Support Oncol; 2010; 8(2 Suppl 1):10-5. PubMed ID: 20629453
[TBL] [Abstract][Full Text] [Related]
20. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
Sankhala KK; Pandya DM; Sarantopoulos J; Soefje SA; Giles FJ; Chawla SP
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1607-14. PubMed ID: 19929449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
